Second Sight Appoints David Jacques as Vice President of Research and Development
Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of
implantable visual prosthetics that provide some useful vision to blind patients, today announced the appointment of David Jacques
as Vice President of Research and Development.
"David has over 30 years of experience in the medical and semiconductor equipment industries. Since June 2016, he has been an
important contributor as a consultant to our R&D team, so I am pleased that he has joined us full-time as we execute our
R&D strategy,” stated Will McGuire, President and CEO of Second Sight.
“David will have responsibility for all areas of research and development as we continue strengthening an organization focused
on delivering new, innovative products to restore sight to an increasing population of blind individuals. David’s proven leadership
skills in motivating engineering teams will complement our efforts to expand the commercial presence of the Argus II® Retinal
Prosthesis to ultimately address the nearly eight million individuals worldwide who are blind due to causes that today have no
treatment," added McGuire.
David’s experience includes senior leadership roles and consulting positions at multiple medical device companies, including
Stereotaxis, Intuitive Surgical, Volcano and others. He is a graduate of the University of Arizona, with a BS in Electrical
Engineering.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe to profound Retinitis Pigmentosa. The Argus II works by
converting images captured by a miniature video camera mounted on the patient's glasses into a series of small electrical pulses,
which are transmitted wirelessly to an array of electrodes implanted on the surface of the retina. These pulses are intended to
stimulate the retina's remaining cells, resulting in the perception of patterns of light in the brain. The patient then learns to
interpret these visual patterns, thereby regaining some visual function. The Argus II is the first artificial retina to receive
widespread approval, and is offered at approved centers in Canada, France, Germany, Italy, Saudi Arabia, Spain, Turkey, United
Kingdom, and the U.S.
About Second Sight
Second Sight's mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has developed and manufactures the Argus II Retinal Prosthesis System.
Second Sight is currently underway in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related
Macular Degeneration. Second Sight is also developing the Orion™ I Visual Cortical Prosthesis to restore some vision to
individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters are in Sylmar,
California, and European Headquarters are in Lausanne, Switzerland. For more information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," “strives,” "may," "will," "expects," "intends," "believes," "should," and similar expressions or the negative versions
thereof and which also may be identified by their context. All statements that address operating performance or events or
developments that Second Sight expects or anticipates will occur in the future are forward-looking statements. While management has
based any forward looking statements included in this release on its current expectations, the information on which such
expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual
results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of
Operations sections of our Annual Report on Form 10-K as filed on March 11, 2016, as amended on August 8, 2016, and our
other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and
uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
Investor Relations:
Institutional Investors
In-Site Communications, Inc.
Lisa Wilson, 212-452-2793
President
lwilson@insitecony.com
or
Individual Investors
MZ North America
Greg Falesnik, 949-385-6449
Managing Director
greg.falesnik@mzgroup.us
View source version on businesswire.com: http://www.businesswire.com/news/home/20170302005125/en/